Amiodarone - Critical Care Medications
TLDRIn this educational video, Eddie Watson from ICU Advantage explores the versatile medication amiodarone, used for various arrhythmias in critical care. Initially introduced in 1961 and later repurposed in 1974, amiodarone is a class 3 antiarrhythmic that impacts the cardiac action potential by blocking potassium flow. Watson discusses its mechanism, side effects, and dosing for cardiac arrest and arrhythmias, emphasizing its importance in ICU settings and the need for careful monitoring due to potential toxicities.
Takeaways
- 💡 Amiodarone is a medication used in critical care for various reasons, making it an essential drug for healthcare professionals to know.
- 🕰️ Amiodarone was first discovered in 1961, initially used for chest pain, and later reintroduced in 1974 for treating arrhythmias.
- 💊 Amiodarone, also known as Amio, Cordarone, or Cordurone, is classified as a Class 3 antiarrhythmic drug.
- 🔬 Class 3 antiarrhythmics work by blocking or slowing the flow of potassium out of cardiac cells, affecting the action potential and conduction of electrical impulses.
- 🌟 Amiodarone has unique properties, including effects on sodium, calcium, and its beta and alpha adrenergic antagonistic effects, acting as a beta blocker.
- ⚠️ Side effects of Amiodarone include pulmonary toxicity, thyroid dysfunction, cardiac effects, and hepatotoxicity, with risks increasing with higher doses and longer administration.
- 🚫 Amiodarone should be avoided in patients with decreased lung function due to its potential for pulmonary toxicity.
- 💡 Amiodarone is recommended by the American Heart Association for use during cardiac arrest, particularly for pulseless ventricular tachycardia (VTAC) and ventricular fibrillation (VF).
- 💊 Dosage for Amiodarone in cardiac arrest includes an initial 300 mg IV push followed by 150 mg IV push if no conversion occurs.
- 🔄 Amiodarone is used for various arrhythmias, including atrial fibrillation with rapid ventricular response, atrial flutter, and stable supraventricular tachycardias.
- 🛑 Amiodarone should not be used for arrhythmias resulting from the Wolff-Parkinson-White (WPW) syndrome unless other treatments have failed.
Q & A
What is the primary focus of the lesson presented in the transcript?
-The primary focus of the lesson is to discuss the medication amiodarone, its uses, how it works, and its side effects, especially in the context of critical care.
Who is the presenter of the lesson and what is his goal?
-The presenter is Eddie Watson, and his goal is to give viewers the confidence to succeed in the ICU by making complex critical care topics easy to understand.
What is the historical background of amiodarone mentioned in the script?
-Amiodarone was first discovered in 1961, initially used for chest pain, pulled from the market in 1967 due to side effects, and then found its use in treating arrhythmias in 1974, leading to its reintroduction to the market.
How is amiodarone classified among antiarrhythmic medications?
-Amiodarone is classified as a Class 3 antiarrhythmic medication.
What is the mechanism of action of Class 3 antiarrhythmics like amiodarone?
-Class 3 antiarrhythmics work by blocking or slowing the flow of potassium out of the cell during the repolarization phase, which increases the duration and refractory phase of both pacemaker cells and myocytes.
What are some unique properties of amiodarone in terms of its effects on the heart?
-Amiodarone is unique in that it has effects on sodium, calcium, as well as some beta and alpha adrenergic antagonistic effects, meaning it also acts as a beta blocker.
What are the major side effects of amiodarone that the script warns about?
-The major side effects discussed are pulmonary toxicity, fibrosis, acute respiratory distress syndrome (ARDS), thyroid dysfunction, cardiac effects like bradycardia, hypotension, and hepatotoxicity.
How does the American Heart Association (AHA) recommend using amiodarone during cardiac arrest?
-The AHA recommends amiodarone for use in the algorithm for pulseless ventricular tachycardia (VTAC) and ventricular fibrillation (VFIB), with a dosage of 300 mg IV push after defibrillation and the first dose of epinephrine, followed by another 150 mg IV push if no conversion occurs.
What is the typical dosing regimen for amiodarone when used for arrhythmias?
-The dosing for arrhythmias typically involves a loading IV dose of 150 mg in 100 ml over 10 minutes, followed by a continuous infusion starting at 1 mg per minute for the first six hours, then reducing to 0.5 mg per minute for 18 hours.
Why should amiodarone not be used in patients with AFIB resulting from WPW syndrome?
-Amiodarone should not be used in patients with AFIB resulting from WPW syndrome unless they are unresponsive to all other medications and cardioversion, as it may worsen the condition due to its potential to prolong the QT interval.
What precautions should be taken when administering the loading dose of amiodarone?
-The loading dose should not be rapid-bolused to avoid profound bradycardia and hypotension. It should be administered over 10 minutes.
Outlines
💊 Introduction to Amiodarone and its Importance in Critical Care
This paragraph introduces the topic of the video, which is amiodarone, a medication frequently used in critical care for various reasons despite not being exclusively for critical care. Eddie Watson, the presenter, welcomes viewers back to ICU Advantage and emphasizes the goal of making complex critical care topics easy to understand. He invites viewers to subscribe and engage with the channel for updates on new lessons and to test their knowledge at icuadvantage.com. The paragraph also mentions that notes and additional benefits are available for YouTube and Patreon members. Amiodarone, discovered in 1961 and initially used for chest pain, was pulled from the market in 1967 due to side effects but returned in 1974 for arrhythmia treatment. It is classified as a class 3 antiarrhythmic, which works by blocking or slowing the flow of potassium out of cardiac cells during repolarization, thus affecting the action potential of myocytes and pacemaker cells. Amiodarone is unique for its additional effects on sodium, calcium, and as a beta blocker.
🚑 Amiodarone's Side Effects and Usage in Critical Care
The second paragraph delves into the potential side effects of amiodarone, which are largely dose-dependent and increase with higher doses and longer administration times. Major side effects include pulmonary toxicity, thyroid dysfunction, and hepatotoxicity. The paragraph advises caution with patients who have decreased lung function and the importance of monitoring liver function. Moving on to the uses of amiodarone in critical care, it can be administered orally, as an IV push, or as a continuous IV infusion. The American Heart Association recommends amiodarone for cardiac arrest during ACLS protocols, specifically for pulseless ventricular tachycardia (VTAC) and ventricular fibrillation (VF), despite limited evidence for its effectiveness. The dosing for arrhythmias involves a loading IV dose followed by a continuous infusion, with precautions against rapid bolus to prevent bradycardia and hypotension. The paragraph concludes with a summary of the video's content, including the mechanism of action, side effects, and common uses of amiodarone in the ICU, and encourages viewers to like, subscribe, and support the channel for further educational content.
Mindmap
Keywords
💡Amiodarone
💡Critical Care
💡Class 3 Antiarrhythmic
💡Action Potential
💡Arrhythmias
💡Pulmonary Toxicity
💡Thyroid Function
💡Cardiac Effects
💡Hepatic Toxicity
💡Dosing
💡ICU Advantage
Highlights
Amiodarone is a medication frequently used for various reasons in critical care.
Amiodarone was discovered in 1961 and initially used for chest pain before being pulled from the market due to side effects.
It was reintroduced in 1974 for the treatment of arrhythmias and is classified as a class 3 antiarrhythmic.
Class 3 antiarrhythmics work by blocking or slowing the flow of potassium during the repolarization phase.
Amiodarone's effects include slowing the conduction of SA and AV nodes and prolonging the refractory phase of myocytes.
Amiodarone has multiple effects, including on sodium, calcium, and as a beta and alpha adrenergic antagonist.
Pulmonary toxicity, fibrosis, and ARDS are potential side effects of amiodarone, especially with higher doses and longer durations.
Amiodarone can affect thyroid function due to its structural similarity to thyroxine and iodine content.
Cardiac effects such as bradycardia, hypotension, and possible ventricular arrhythmias are associated with amiodarone use.
Hepatic toxicity is another significant side effect, necessitating liver function monitoring.
Amiodarone is recommended by the American Heart Association for use during cardiac arrest in ACLS protocols.
Despite recommendations, evidence for amiodarone's benefit in cardiac arrest is not strong, and its effectiveness is questioned.
Amiodarone is used for various arrhythmias, including atrial fibrillation with rapid ventricular rate.
Amiodarone can convert 60-70% of patients with new-onset AFib back to normal sinus rhythm.
Amiodarone should not be used in patients with AFib resulting from WPW syndrome unless other treatments fail.
Dosing for arrhythmias includes a loading dose followed by a continuous infusion with specific rates.
An inline filter is required when administering the continuous infusion to prevent precipitates.
The lesson provides a comprehensive review of amiodarone, its mechanism, side effects, and uses in critical care.
Transcripts
5.0 / 5 (0 votes)
Thanks for rating: